Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00DQX
|
|||
| Former ID |
DCL000578
|
|||
| Drug Name |
Motesanib
|
|||
| Synonyms |
N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Discontinued in Phase 3 | [1], [2] | |
| Company |
Amgen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23N5O
|
|||
| Canonical SMILES |
CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C
|
|||
| InChI |
1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
|
|||
| InChIKey |
RAHBGWKEPAQNFF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 453562-69-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16771727, 23766907, 47208329, 50100087, 56269724, 56394911, 57376990, 79661629, 85195381, 103694305, 109693533, 123044253, 123051115, 125711982, 126584079, 126634886, 126665970, 126728315, 134339136, 135216214, 135685150, 135685151, 135685170, 135686092, 135686093, 135686110, 135686111, 136368105, 137010936, 137276049, 142660693, 143498107, 144115596, 152234936, 152258139, 152344215, 160646978, 162201686, 163108960, 164043534, 164230685, 174561000, 177748728, 178102288, 180371640, 184826919, 198946291, 223385949, 223670551, 226547309
|
|||
| ChEBI ID |
CHEBI:51098
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5660). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011016) | |||
| REF 3 | Clinical pipeline report, company report or official report of Amgen (2009). | |||
| REF 4 | Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10;27(23):3794-801. | |||
| REF 5 | Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 2008 May;17(5):741-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.